InterVene
South San Francisco, CA · Healthcare · 50 employees
InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs
Funding history
- Series A — $13.0M — Oct 2024
- Seed — $1.5M — Mar 2023
- Seed — $2.2M — Jun 2017
Recent signals
- Oct 07, 2024: Raised $13.0M in Series A
- Mar 07, 2023: Raised $1.5M in Seed
- Jun 07, 2017: Raised $2.2M in Seed
See plans & pricing → Track InterVene’s funding, hiring, and signals — with verified contacts — on Fundz.